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Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal
peptide (VIP) through the binding of vasoactive intestinal peptide receptors (VIPRs),
perform a wide variety of effects in human cancers, including glioblastoma multiforme
(GBM). This tumor is characterized by extensive areas of hypoxia, which triggers the
expression of hypoxia-inducible factors (HIFs). HIFs not only mediate angiogenesis
but also tumor cell migration and invasion. Furthermore, HIFs activation is linked to
epidermal growth factor receptor (EGFR) overexpression. Previous studies have shown
that VIP interferes with the invasive nature of gliomas by regulating cell migration.
However, the role of VIP family members in GBM infiltration under low oxygen tension
has not been clarified yet. Therefore, in the present study we have investigated, for
the first time, the molecular mechanisms involved in the anti-invasive effect of PACAP
or VIP in U87MG glioblastoma cells exposed to hypoxia induced by treatment with
desferrioxamine (DFX). The results suggest that either PACAP or VIP exert an anti-
infiltrative effect under low oxygen tension by modulating HIFs and EGFR expression,
key elements involved in cell migration and angiogenesis. These peptides act through
the inhibition of PI3K/Akt and MAPK/ERK signaling pathways, which are known to have
a crucial role in HIFs regulation.
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INTRODUCTION
Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide
(VIP) belong to a family of polypeptides, comprising also peptide histidine-methionine (PHM),
secretin, glucagon, glucagon-like peptide (GLP), glucose-dependent insulinotropic polypeptide
(GIP), growth hormone releasing hormone (GHRH), and helodermin (Sherwood et al., 2000).
They have sequence homology and explicate their functions by binding to vasoactive intestinal
peptide receptors (VIPRs) including PAC1, VPAC1, and VPAC2 receptors.
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Pituitary adenylate cyclase-activating polypeptide interacts,
with high affinity, to PAC1 receptor, whereas both PACAP and
VIP can activate either VPAC1 or VPAC2 receptor (Harmar et al.,
2012; Tang et al., 2014). VIPRs consist of seven transmembrane
domains, a large N-terminal fragment that includes the binding
site for PACAP/VIP and an intracellular C-terminal region
coupled to heterodimeric G-proteins associated with various
signal transduction pathways (Laburthe et al., 2002). Indeed, their
stimulation ultimately results in the activation of Protein Kinase
A (PKA) (Couvineau et al., 2003; Dickson et al., 2006; Dickson
and Finlayson, 2009; Vaudry et al., 2009), Protein Kinase C
(PKC) (Vaudry et al., 2000), MAPKs (mitogen-activated protein
kinases) (Barrie et al., 1997; Lelièvre et al., 1998), NF-κB signaling
pathways (Delgado and Ganea, 1999).
Pituitary adenylate cyclase-activating polypeptide and
VIP perform a regulatory role as neurotransmitters and/or
neuromodulators in the peripheral and central nervous system
(CNS). They are involved in different biological processes such
as neuronal survival, stress response, cell division, neuro-,
and glio-protective actions (Cavallaro et al., 1995; Canonico
et al., 1996; D’Agata et al., 1996; D’Agata and Cavallaro, 1998;
Jaworski, 2000; Castorina et al., 2008, 2010a, 2014; Giunta
et al., 2012). Furthermore, they play neuroprotective action
in various neurodegenerative diseases, comprising Parkinson’s
disease (Brenneman, 2007; Dejda et al., 2008; Reglodi et al., 2011;
Seaborn et al., 2011; Waschek, 2013). Different studies have
also shown that these peptides, through the binding to VIPRs,
play a wide variety of effects in human tumors, including GBM
(Robberecht et al., 1993, 1994; Oka et al., 1998; Reubi et al., 2000;
Juarranz et al., 2001; Isobe et al., 2003). However, their role seems
to be controversial depending on histopathological features of
cancer. In fact, in some instances, PACAP and VIP stimulate
tumor mass growth whereas in others they show antiproliferative
effect (Castorina et al., 2008, 2012; Giunta et al., 2010; D’Amico
et al., 2013).
More recently, Cochaud et al. (2015) have suggested that VIP
interferes with the infiltrative nature of GBM by regulating cell
migration. This tumor is the most common and malignant form
of primary brain cancer in adults (Wen and Kesari, 2008). Its poor
prognosis is related to the therapeutic failure, mainly due to its
highly invasive features leading to local or distant recurrences.
Indeed, neoplastic cells can migrate to the surrounding tissue,
travel along white matter tracts and blood vessel walls to reach
other brain areas (Nakada et al., 2007; Dunn et al., 2012).
Glioblastoma multiforme, like other solid tumors, contains
extensive areas of hypoxia associated to tissue necrosis and
development of aberrant neovascularization (Kaur et al., 2005).
In fact, in these regions, low oxygen tension induces expression
of hypoxia-inducible factors (HIFs) which mediate the adaptive
response through new blood vessels formation. These factors are
heterodimeric complexes, including an oxygen-labile α- and a
more stable β-subunit (ARNT), involved either in physiological
or pathological angiogenesis (Semenza, 1999a,b; Maynard and
Ohh, 2004).
In humans there are three HIF-α genes: HIF-1α, HIF-2α, and
HIF-3α. In particular, HIF-1α is the key modulator in cellular
response to low oxygen tension. It is overexpressed in GBM
thereby contributing to intense angiogenesis (Kaur et al., 2005;
Zagzag et al., 2006). HIF-2α is also induced by hypoxia, but
it plays a major role under chronic insult (Tian et al., 1997;
Koh et al., 2011). Several studies have associated HIF-2α up-
regulation to development of an aggressive tumor phenotype
(Helczynska et al., 2008; Qing and Simon, 2009; Koh and Powis,
2012). Moreover, overexpression of both HIF-1α and HIF-2α has
been related to poor prognosis of different cancer, including GBM
(Holmquist-Mengelbier et al., 2006; Franovic et al., 2009).
In this tumor, these factors are not only involved in
angiogenesis but they also stimulate tumor cell migration and
invasion (Zagzag et al., 2006; Fujiwara et al., 2007). Furthermore,
the hypoxic microenvironment and activation of HIF-2α in the
core of solid tumors induces overexpression of epidermal growth
factor receptor (EGFR). Amplification and/or mutations of EGFR
are commonly found in GMB. EGFR overexpression, indeed, has
been recognized as a prognostic marker of advanced tumoral
stage, resistance to standard therapy and reduced patient’s
survival (Blehm et al., 2006; Halatsch et al., 2006; Franovic
et al., 2007). Under low oxygen tension, accumulation of elevated
EGFR levels, in turn mediated by increased HIF-2α, participates
to autonomy in tumor cell growth through an autocrine signaling
mechanism (Franovic et al., 2007).
A previous study has suggested the involvment of VIP in
tumor invasion, but the role of PACAP and its receptors in
this biological context still needs to be elucidated. Considering
the relevance of the hypoxic microenvironment in determining
tumor aggressivity, in the present study we investigated the
effect of these peptides in the modulation of HIFs and EGFR
expression, both key elements involved in cell migration and
angiogenesis. To this end, we also analyzed the underlying
molecular pathways by focusing on phosphoinositide three
kinase (PI3K)/Akt and mammalian mitogen activated protein
kinase/Erk kinase (MAPK/ERK) signaling cascades, since, as
previously demonstrated, they interfere with HIF-1α and HIF-2α
expression (Mottet et al., 2002; Lim et al., 2004; Park et al., 2011;
Zhang et al., 2011).
Our results suggest that these peptides exert an anti-invasive
action under hypoxia by modulating HIFs and EGFR expression.
This effect is mediated through the inhibition of PI3K/Akt and
MAPK/ERK signaling pathways. These data confirm previous
findings suggesting that tumor microenvironment may act as an
oncogene promoter triggering the autonomous growth of tumor
cells. Therefore, the identification of molecules modulating
the hypoxic event might give new insights in the therapeutic
approach to GBM.
MATERIALS AND METHODS
Human Brain Samples and Cell Lines
The study was performed on glioblastoma frozen sections
from a sample provided by Anatomic Pathology of “G.F.
Ingrassia” Department, after patient’s signed informed consent.
Experiments were also carried on human glioblastoma cell line,
U87MG (ATCCC number #HTB-14). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
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with 10% of heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin and 100-µg/ml streptomycin (Sigma–
Aldrich, Steinheim, Germany). They were incubated at 37◦C in a
humidified atmosphere with 5% CO2 as previously described by
Maugeri et al. (2016). Cells grown under hypoxia were exposed
for 24 h to 100 µM desferrioxamine mesylate salt (DFX) (Sigma–
Aldrich), an hypoxia-mimetic agent, which induces hypoxia via
inhibition of the HIF prolyl hydroxylases (Epstein et al., 2001;
Hirsilä et al., 2005). As compared to the cell incubation method in
hypoxic chamber, this offers the advantage to the experimentator
to open the culture plate/dish/flask many times without affecting
the hypoxic condition.
Treatments
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38,
100 nM; cat no. A1439, Sigma–Aldrich), VIP, (100 nM; cat no.
V3628, Sigma–Aldrich), PACAP receptor antagonist (PACAP6–
38, 10 µM; cat no.3236, Tocris Biosciences, Bristol, UK)
and selective VIP receptor antagonist (D-p-Cl-Phe6,Leu17-VIP,
10 µM; cat no. 3054, Tocris Biosciences) were added to U87MG
cells for 24 h in normoxic or hypoxic condition.
Inhibition of PI3K/Akt and MAPK/ERK signaling pathways
was performed following a pretreatment of 30 min with a
PI3K (Wortmannin, 10 µM; cat no.1232/5, Tocris Biosciences)
or MEK1 inhibitor (PD98059, 50 µM; cat no. #P215, Sigma–
Aldrich,) under normoxia or hypoxia (Aleppo et al., 1992;
Castorina et al., 2010b).
Cell Migration Assay
After trypsinization, U87MG cells were resuspended, counted
and seeded onto a six-well plate at a density of 5× 104 cells/well.
A scratch was made in cell monolayer with a 200-µL pipette tip.
Then, to remove the suspended cells, it was washed twice with
PBS and incubated in medium containing 100 nM PACAP38 or
100 nM VIP or 10 µM Wortmannin or 50 µM PD98059, either
in normoxic or hypoxic condition. The wounded areas were
visualized under a microscope for quantification. The distance
that the advancing cells had moved into the cell-free (wound) area
was measured after 24 h by staining with crystal violet. Migration
was calculated as the average number of cells observed in five
random high power wounded fields/per well in duplicate wells.
Western Blot Analysis
Western blot analysis was performed according to the procedures
previously described by Magro et al. (2011). Proteins were
extracted with buffer containing 20 mM Tris (pH 7.4), 2 mM
EDTA, 0.5 mM EGTA; 50 mM mercaptoethanol, 0.32 mM
sucrose and a protease inhibitor cocktail (Roche Diagnostics,
Monza, Italy) using a Teflon-glass homogenizer and then
sonicated twice for 20 s using an ultrasonic probe, followed
by centrifugation at 10,000 × g for 10 min at 4◦C. Protein
concentrations were determined by the Quant-iT Protein Assay
Kit (Invitrogen,Carlsbad, CA, USA). About 65 µg from fresh
frozen section per sample, and about 30 µg of protein
homogenate were diluted in 2X Laemmli buffer (Invitrogen),
heated at 70◦C for 10 min and then separated on a Biorad
Criterion XT 4–15% Bis-tris gel (Invitrogen) by electrophoresis
and then transferred to a nitrocellulose membrane (Invitrogen).
Blots were blocked using the Odyssey Blocking Buffer (Li-Cor
Biosciences, Nebraska, NE, USA). The transfer was monitored
by a prestained protein molecular weight marker [BioRad
Laboratories, Segrate (MI), Italy]. Immunoblot analysis was
performed by using appropriate antibodies: rabbit anti-PACAP
(H-76, cat no. sc-25439, Santa Cruz Biotechnology, Texas City,
TX, USA 1:200), mouse anti-VIP (H-6, cat no. sc-25347, Santa
Cruz Biotechnology; 1:100), (rabbit anti-PAC1 receptor (H-55,
cat no.sc-30018, Santa Cruz Biotechnology; 1:300), rabbit anti-
VPAC1 (H-130, cat no. sc-30019, Santa Cruz Biotechnology;
1:200), rabbit anti-VPAC2 (H-50, cat no. sc-30020, Santa Cruz
Biotechnology; 1:200), mouse anti- HIF-1alpha (cat.n. NB100-
105, Novus Biologicals, Littleton, CO, USA 1:500), rabbit anti-
HIF-2alpha (cat.n. NB100-122, Novus Biologicals, 1:500), rabbit
anti- EGFR (cat.n. sc-03 Santa Cruz Biotechnology), rabbit anti-
phospho Akt (Ser473 residue) (D9E, cat no. #4060, Cell Signaling,
Danver, MA, USA; 1:1000), rabbit anti-total Akt (C67E7, cat
no. #4691, Cell Signaling; 1:1000), mouse anti-phospho Erk-
1/2 (Thr202 and Tyr204 residues) (pT202/pY204.22A, cat no.
sc-136521, Santa Cruz Biotechnology; 1:200), mouse anti-total
Erk-1/2 (MK1, cat no. sc-135900, Santa Cruz Biotechnology;
1:200), and rabbit anti-β-tubulin (cat n.sc-9104, Santa Cruz
Biotechnology; 1:500). The secondary antibody goat anti-rabbit
IRDye 800CW (cat #926-32211; Li-Cor Biosciences) and goat
antimouse IRDye 680CW (cat #926-68020D, Li-Cor Biosciences)
were used at 1:20,000 and 1:30,000, respectively. Blots were
scanned with an Odissey Infrared Imaging System (Odyssey).
Densitometric analyses of Western blot signals were performed
at non-saturating exposures and analyzed using the ImageJ
software1 (NIH, Bethesda, MD, USA). Values were normalized
to β-tubulin, which served as loading control, as previously
described by Maugeri et al. (2015).
Immunohistochemical Analysis
Fresh-frozen sections of a surgically resected tumor included in
OCT were cut and fixed in 4% paraformaldehyde for 30 min.
Then, they were treated with 3% H2O2 in methanol for 10 min
to inhibit the endogenous peroxidase activity as previously
described by D’Agata et al. (2000). To reduce non-specific
staining, sections were treated with 1% bovine serum albumin
(BSA) in PBS for 1 h, and incubated overnight at 4◦C with
appropriate antibody. The sections were rinsed in PBS and
incubated with diaminobenzidine (DAB) for 5 min. Hematoxylin
was used as nuclear counterstain. The stained sections were
dehydrated through graded alcohols, cleared in xylene, and
covered with neutral balsam.
Statistical Analysis
Data are represented as mean ± standard error (SEM). One-way
analysis of variance (ANOVA) was used to compare differences
among groups, and statistical significance was assessed by the
Tukey–Kramer post hoc test. The level of significance for all
statistical tests was set at p ≤ 0.05.
1http://rsb.info.nih.gov/ij/index.html
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RESULTS
Expression of PACAP, VIP, VIPRs, HIF-1α,
HIF-2α, and EGFR in Human
Glioblastoma
As previously demonstrated, here, we found that the precursor
proteins of PACAP and VIP, and VIPRs are expressed in
GBM; however, precursor peptides levels seemed to be lower as
compared to their receptors (Figure 1A). To correlate this finding
with tumor malignancy, we have confirmed HIF-1α, HIF-2α,
and EGFR expression in sections from the same frozen sample
by western blot analysis (Figure 1B). Furthermore, we have
determined their tissue localization by immunohistochemical
analysis. An heterogeneous tissue staining of HIF-1α, HIF-2α,
and EGFR has been observed in this tumor (Figure 1B).
PACAP and VIP Antagonize
Hypoxia-Mediated GBM Cell Migration
by Reducing HIFs and EGFR Expression
To characterize the role of these peptides in hypoxic areas
of GBM, we have analyzed the expression of PACAP or VIP
precursor proteins in U87MG tumor cells, grown for 24 h under
normoxia or hypoxia. As shown in Figure 2, both precursor
peptides and VIPRs receptors were expressed in these cells under
normal oxygen tension, however, their levels were significantly
increased following the hypoxic insult (Figure 2B, ∗p < 0.05
or ∗∗∗p < 0.001 vs. normoxia). In view of this result, we
have investigated the effect of these peptides on proliferation
and invasion of gliomas cells during hypoxic process, which
represents a distinctive biological feature of malignant cells.
Therefore, we have analyzed the effect of 100 nM PACAP and VIP
on tumoral cells invasivity. At this concentration, both peptides
showed antiproliferative properties, as previously described by
D’Amico et al. (2013). The dose used is higher as compared
to their tumor tissues level. However, considering that tumoral
mass is highly heterogeneous, comprehending various cell types
with different mutations and degree of differentiation, in the
present study, we decided to omit the characterization of their
physiological role in cancer. Then, we have focused on the effect
of exogenous peptides in a homogeneous cell culture. As shown
in Figure 3, migration rate increased in GBM cells exposed to
DFX as compared to normoxic control (Vhl). PACAP or VIP
treatment significantly decreased cell invasion both under normal
or low oxygen tension. Similarly, treatment with Wortmannin
or PD98059, a PI3K and MEK1 inhibitors, respectively, induced
significant reduction of cell’s migration confirming that tumor
cell invasion and proliferation is mediated via activation of
PI3K/AKT and ERK pathway (∗∗∗p< 0.001 vs. Vhl in normoxia;
###p< 0.001 vs. Vhl in hypoxia).
Based on these results, we further explored whether these
peptides have performed their effect through modulation of HIFs
and EGFR expression. PACAP treatment induced a significant
reduction of HIF-1α, HIF-2α, and EGFR, either in normoxia
or hypoxia, as compared to control. Furthermore, to confirm
whether the effect of this peptide was mediated through the
selective activation of PAC1 receptor, we also treated cells with
a PACAP antagonist, such as PACAP 6–38, under normoxic
or hypoxic condition. PACAP 6–38 treatment restored the
expression of these proteins to their relative control levels, both
in normoxia or hypoxia, confirming the involvement of PAC1
receptor (Figure 4B, ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs.
Vhl; ###p < 0.001 vs. Vhl in hypoxia; $$p < 0.01 $$$p < 0.001 vs.
PACAP).
Similarly to PACAP, also VIP treatment significantly reduces
expression levels of HIFs and EGFR as compared to relative
controls. However, VIP antagonist treatment was not able to
restore HIF-1α, HIF-2α, and EGFR expression to control levels
(Figure 4B, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. Vhl;
###p< 0.001 vs. Vhl in hypoxia).
PACAP and VIP Decrease HIFs and EGFR
Expression, through Inhibition of
PI3K/Akt and MAPK/ERK Pathways
Remarkably, PI3K/Akt and the MAPK/ERK signaling cascades
are aberrantly activated in many cancers, including GBM. The
stimulation of these pathways leads to increase of HIF-1α and
HIF-2α levels, which are involved in the aggressive behavior
of tumor and promotion of angiogenesis. Furthermore, HIFs
promote EGFR activation. To confirm this crucial link, we
have treated cells with Wortmannin or PD98059. As shown
in Figure 5, both substances induced a statistically significant
decrease of HIF-1α, HIF-2α and EGFR expression as compared to
control cells grown either under normoxia or hypoxia (Figure 5,
∗∗p < 0.01, ∗∗∗p < 0.001 vs. Vhl in normoxia; ###p < 0.001 vs.
Vhl in hypoxia).
To investigate whether PACAP and VIP regulate HIFs and
EGFR levels, through inhibition of these signaling pathways,
we assessed their effect on phosphorylation of two signaling
proteins. As shown in Figure 6, Akt and ERK1/2 are activated
to comparable levels both under normoxia or hypoxia. We have
hypothesized that this may be due to lack of the functional
gene opposing tumor suppressor lipid phosphatase (PTEN) in
the glioma cell line, U87MG, used. This is a tumor suppressor
gene acting as a negative regulator of both PI3K/Akt and ERK1/2
signaling pathways (Li et al., 1997; Koul, 2008; Chetram and
Hinton, 2012; Song et al., 2012). Instead, the treatment of
U87MG cells with these peptides significantly decreased the level
of phosphorylated Ser473 AKT and ERK1/2 both in normoxia
and hypoxia (Figures 6A,B, ∗∗∗p < 0.001 vs. Vhl in normoxia;
###p< 0.001 vs. Vhl in hypoxia).
DISCUSSION
Pituitary adenylate cyclase-activating polypeptide and VIP are
widely expressed in peripheral tissues, CNS and in a wide
variety of human tumors, including GBM (Robberecht et al.,
1993, 1994; Oka et al., 1998; Reubi et al., 2000; Juarranz
et al., 2001; Isobe et al., 2003). They exert various effects
by interacting to VIPRs depending on transcript variants
express in each cell type. By focusing on cancer, many studies
have highlighted their controversial role in the progression
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FIGURE 1 | Expression of PACAP, VIP, VIPRs, HIF-1α, HIF-2α, and EGFR in glioblastoma multiforme (GBM). (A) Representative immunoblot of PACAP and
VIP precursor peptides and PAC1R, VPAC1R, and VPAC2R expression on frozen glioblastoma sample. (B) Representative immunoblot and photomicrographs of
signals detected by antibodies direct against HIF-1α, HIF-2α, and EGFR in a frozen glioblastoma sample.
FIGURE 2 | Expression of PACAP, VIP, PAC1R, VPAC1R, and VPAC2R in glioblastoma cells under normoxic or hypoxic conditions. (A) Representative
immunoblot of PACAP and VIP precursor peptides and PAC1R, VPAC1R, and VPAC2R expression on U87MG cells grown normoxia or exposed to hypoxia. (B) The
bar graphs show quantitative analysis of signals obtained on immunoblots resulting from three independent experiments. Relative band densities were quantified by
using ImageJ software. Protein levels are expressed as arbitrary units obtained after normalization to β-tubulin which was used as loading control. Data represent
means ± SEM (∗p < 0.05 or ∗∗∗p < 0.001 vs. Normoxia as determined by unpaired two-tailed Student t-test).
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FIGURE 3 | Effect of PACAP, VIP, PI3K, and MEK1 inhibitors on U87-MG
cells migration. Cells monolayer was scraped by a pipette tip and incubated
with PACAP, VIP, Wortmannin or PD98059 for 24 h under normoxia or
hypoxia. The wounded areas were visualized under a microscope for
quantification. Migration was calculated as the average number of cells
observed in five random high power wounded fields/per well in duplicate
wells. In the bar graph values are expressed as percentage of control.
(∗∗∗p < 0.001 vs. Vhl under normoxia; ###p < 0.001 vs. Vhl under hypoxia).
of malignancies. In particular, they have shown a prominent
growth effect on some common neoplasms, such as lung,
gut, prostate and immune system neoplastic diseases (Reubi
et al., 2000; Moody et al., 2001; Schulz et al., 2004). However,
as we show in this paper, they exert anti-invasive effect,
in other tumors, including GBM (Vertongen et al., 1996;
Cochaud et al., 2015). During tumorigenesis, hypoxic areas
are generated in the neoplastic mass when deregulation in
cell proliferation leads to an increase in tissue amount, not
supported by an adequate oxygen supply. Hypoxia plays a
key role in malignancy not only by stimulating angiogenesis
but also by increasing cellular migration. Therefore, in the
present study, we evaluated the effect of PACAP and VIP on
tumor cell infiltration grown in a hypoxic microenvironment.
The present results show that the endogenous expression
of PACAP and VIP precursor peptides, and relative VIPRs
was increased under hypoxia (Figure 2). Furthermore, these
neuropeptides significantly abrogated the hypoxia-enhanced
migration of U87MG cells (Figure 3), suggesting that they
might play a pivotal role in cellular invasion in GMB hypoxic
areas. It is remarkable that HIFs, the main regulators of
the transcriptional response to hypoxia, represent one of the
distinctive hallmarks in malignancy. Here, we have found
that PACAP or VIP treatment, decreases the expression
levels of both HIF-1α and HIF-2α. Concomitantly, we have
found that their administration have induced a significant
reduction in EGFR levels, a biomarker of cell proliferation.
The present data, consistently with previous papers, indicate
that hypoxia promotes an oncogenic program which results
from the translational up-regulation of EGFR, predominantly
depending on HIFs levels (Franovic et al., 2007, 2009). This
view is also corroborated by the high expression of PACAP,
VIP, VIPRs, HIFs, and EGFR in the frozen tumor sample
(Figure 1).
FIGURE 4 | Effect of PACAP, PACAP6-38, VIP, and VIP antagonist on expression of HIF-1α, HIF-2α, and EGFR in U87-MG cells under normoxia and
hypoxia. (A) Representative immunoblots of HIF-1α, HIF-2α, and EGFR expression on U87MG cells grown normoxia or exposed to hypoxia. (B) The bar graphs
show quantitative analysis of signals obtained by immunoblots resulting from three independent experiments. Relative band densities were quantified by using
ImageJ software. Protein levels are expressed as arbitrary units obtained after normalization to β-tubulin which was used as loading control. Data represent
means ± SEM (∗p < 0.05, ∗∗p < 0.01, or ∗∗∗p < 0.001 vs. Vhl under normoxia; ###p < 0.001 vs. Vhl under hypoxia $$p < 0.01 or $$$p < 0.001 vs. PACAP, as
determined by one-way ANOVA followed by the Tukey post hoc test).
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FIGURE 5 | Expression of HIF-1α, HIF-2α, and EGFR following inhibition of PI3K/Akt or MAPPK/Erk kinase signaling pathway. (A) Representative
immunoblot of HIF-1α, HIF-2α, and EGFR expression on U87MG cells treated with 10 µM Wortmannin or with 50 µM PD98059 and grown normoxia or exposed to
hypoxia. (B) Relative density of each band was quantified using ImageJ software. Each signal was normalized on correspondent β-tubulin signal. Data are expressed
as mean ± SEM (∗∗p < 0.01 and ∗∗∗p < 0.001 vs. Vhl under normoxia; ###p < 0.001 vs. Vhl under hypoxia as determined by one-way ANOVA followed by the
Tukey post hoc test).
Furthermore, we have investigated whether modulation
of HIFs and EGFR expression is mediated through VIPRs
by treating cells with PAC1 and VPAC1/VPAC2 receptor
antagonists, respectively. The results show that PACAP 6–38
treatment highly increased HIFs and EGFR levels, suggesting that
hypoxia through activation of endogenous PACAP system may
interfere with hypoxia and relative cell proliferation mediated by
EGFR (Figure 4). On the other hand, the VIP receptor antagonist
was ineffective (Figure 4). This lack of effect might result from
a simultaneous block of VPAC1 and VPAC2 receptors, which
mediate different functions by activating various pathways, or,
more simply, might be due to low specificity of the tested
antagonist molecule.
As demonstrated previously, HIFs expression is regulated by
PI3K/Akt and MAPK/ERK signaling pathways (Mottet et al.,
2002; Lim et al., 2004). In addition, Akt phosphorylation
promotes the transformation of anaplastic astrocytoma in GBM,
thereby playing a role as oncogenic modulator. In fact, this
molecule is involved in cell proliferation by acting on some
regulators of cell cycle, apoptosis, and metabolism (Sonoda et al.,
2001a,b). MAPK/ERK pathway activation is also involved in
tumorigenesis by supporting progression and poor-prognosis of
GBM (Kim et al., 2009; Liu et al., 2013).
Our results have confirmed previous data suggesting that
the expression of HIFs and consequently EGFR is mediated
by activation of both pathways. Indeed, as shown in Figure 5,
the pretreatment with a specific PI3K/Akt (wortmannin) or
MAPK/ERK (PD98059) pathway inhibitor, strongly decrease
HIFs and EGFR levels as compared to own control, in cells
grown either in normoxia or exposed to DFX-induced hypoxia.
In future, we are planning to deeply investigate the downstream
phenotypic effects mediated by EGFR under these experimental
conditions.
Thus, we have demonstrated that the anti-invasive effect of
PACAP and VIP in GBM cells is mediated through inhibition of
these pathways. Indeed, the treatment with these peptides reduces
Akt and ERK1/2 phosphorylation which are major targets
of PI3K/Akt or MAPK/ERK signaling cascades, respectively
(Figure 6).
Apparently, these results are in contrast with other studies
showing that PACAP and VIP, through the activation of
cAMP/PKA and PI3K signaling pathways, mediated by
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FIGURE 6 | Phosphorylation of AKT and ERK1/2 in U87-MG cells under normoxia and hypoxia. (A) Representative immunoblots of Ser473-p Akt or
p-Erk1/2 expression on U87MG cells treated with PACAP or VIP under normoxia or hypoxia. (B) The bar graphs show quantitative analysis of signals obtained by
immunoblots resulting from three independent experiments. Relative band densities were quantified by using ImageJ software. Each signal of phosphorylated protein
was normalized to total protein expression. Data are expressed as mean ± SEM (∗∗p < 0.01, ∗∗∗p < 0.001 vs. Vhl under normoxia; ###p < 0.001 vs. Vhl under
hypoxia as determined by one-way ANOVA followed by the Tukey post hoc test).
VIPRs, stimulate a series of transcription factors, which
promote proliferation, expression of nuclear oncogenes and
growth factors in different cell lines (Whitmarsh and Davis,
1996; Casibang et al., 2001). However, this controversial
biological effect might depend by cell or tissue phenotype
examined.
In conclusion, these data suggest that, under low
oxygen tension, PACAP or VIP reduce cell invasion
by acting as negative regulators of HIFs and EGFR
through the inhibition of PI3K/Akt and ERK1/2 signaling
pathways. Further studies are required to clarify whether
PACAP and VIP have the same effects, as observed in
the present study, in GBM cells exposed to hypoxia, not
chemically induced, but through lowering of oxygen tension
(1% O2).
Despite over the last three decades have emerged new
treatments of brain tumors, the survival of patients with GBM
remains very poor. Therefore, new targeted agents in clinical
therapy are needed. Here, we propose that the modulation of
PACAP and VIP receptors system in combination with other
therapies, might represent a new approach to limit invasion of
this devastating tumor.
CONCLUSION
The modulation of hypoxic event and the anti-invasive effect
exerted by some VIP family members might open new insights
in the therapeutic approach to GBM.
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